个人中心 - 老虎社区

小王爱大大王

IP属地：北京

帖子 · 3帖子 · 3
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 小王爱大大王小王爱大大王
  ·2021-07-23
  加油正规的公司不怕的
  非常抱歉，此主贴已删除
  1,896 评论
  3
  分享
  举报
- 小王爱大大王小王爱大大王
  ·2021-02-19
  能不能把不中签的手续费退回来
  据悉诺辉健康因涉嫌重复认购遭港交所调查
  19日讯，据悉，诺辉健康的股份登记处卓佳向曾代客户提交认购申请的券商发信指，按港交所要求，券商需要向港交所确认已采取合适的措施，以拒绝任何重复申请或疑似重复申请；同时，券商要提交认购诺辉健康客户的姓名
  据悉诺辉健康因涉嫌重复认购遭港交所调查
  2,350 评论
  3
  分享
  举报
- 小王爱大大王小王爱大大王
  ·2021-02-17
  老虎应该改改，不中签不要收手续费，太坑了
  老虎暗盘：诺辉健康开涨162%，此前获逾4133倍认购
  2月17日消息，诺辉健康-B暗盘报70港元，较发行价涨162.57%。公司发行约7659.8万股股份，每股定价26.66港元，每手500股，将于2月18日（周四）港股上市。在此前的公开认购阶段，共有
  老虎暗盘：诺辉健康开涨162%，此前获逾4133倍认购
  3,771 3
  9
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3521540189936763","uuid":"3521540189936763","gmtCreate":1558494078964,"gmtModify":1610718387585,"name":"小王爱大大王","pinyin":"xwaddwxiaowangaidadawang","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/c1fd3513a8e4f9a55a759280c02468d9","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":43,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.12","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.68%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.11%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"北京","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":175554998,"gmtCreate":1627043807214,"gmtModify":1627043807214,"author":{"id":"3521540189936763","authorId":"3521540189936763","name":"小王爱大大王","avatar":"https://static.tigerbbs.com/c1fd3513a8e4f9a55a759280c02468d9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3521540189936763","authorIdStr":"3521540189936763"},"themes":[],"htmlText":"加油 正规的公司不怕的","listText":"加油 正规的公司不怕的","text":"加油 正规的公司不怕的","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/175554998","repostId":"1159098067","repostType":4,"isVote":1,"tweetType":1,"viewCount":1896,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":387920074,"gmtCreate":1613711148498,"gmtModify":1613711148498,"author":{"id":"3521540189936763","authorId":"3521540189936763","name":"小王爱大大王","avatar":"https://static.tigerbbs.com/c1fd3513a8e4f9a55a759280c02468d9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3521540189936763","authorIdStr":"3521540189936763"},"themes":[],"htmlText":"能不能把不中签的手续费退回来","listText":"能不能把不中签的手续费退回来","text":"能不能把不中签的手续费退回来","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/387920074","repostId":"1152825532","repostType":4,"repost":{"id":"1152825532","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1613709263,"share":"https://ttm.financial/m/news/1152825532?lang=&edition=full","pubTime":"2021-02-19 12:34","market":"hk","language":"zh","title":"据悉诺辉健康因涉嫌重复认购遭港交所调查","url":"https://stock-news.laohu8.com/highlight/detail?id=1152825532","media":"老虎资讯综合","summary":"19日讯，据悉，诺辉健康的股份登记处卓佳向曾代客户提交认购申请的券商发信指，按港交所要求，券商需要向港交所确认已采取合适的措施，以拒绝任何重复申请或疑似重复申请；同时，券商要提交认购诺辉健康客户的姓名","content":"<p>19日讯，据悉，诺辉健康的股份登记处卓佳向曾代客户提交认购申请的券商发信指，按港交所要求，券商需要向港交所确认已采取合适的措施，以拒绝任何重复申请或疑似重复申请；同时，券商要提交认购诺辉健康客户的姓名及身份证号码等资料予港交所，亦要通知诺辉的保荐人已经提交相关资料。港交所回应表示不针对个别公司。</p><p>主营癌症筛查的诺辉健康招股获106万人热捧，最终只有约逾7万人中签，一手中签率仅2%，比快手的4%更低。</p><p><img src=\"https://static.tigerbbs.com/e81b0893ec16bfbc9aca3d4686848539\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>据悉诺辉健康因涉嫌重复认购遭港交所调查</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n据悉诺辉健康因涉嫌重复认购遭港交所调查\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-02-19 12:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>19日讯，据悉，诺辉健康的股份登记处卓佳向曾代客户提交认购申请的券商发信指，按港交所要求，券商需要向港交所确认已采取合适的措施，以拒绝任何重复申请或疑似重复申请；同时，券商要提交认购诺辉健康客户的姓名及身份证号码等资料予港交所，亦要通知诺辉的保荐人已经提交相关资料。港交所回应表示不针对个别公司。</p><p>主营癌症筛查的诺辉健康招股获106万人热捧，最终只有约逾7万人中签，一手中签率仅2%，比快手的4%更低。</p><p><img src=\"https://static.tigerbbs.com/e81b0893ec16bfbc9aca3d4686848539\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/8d89c7d6ead02a2f98ab35f858ea9f69","relate_stocks":{"06606":"诺辉健康"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152825532","content_text":"19日讯，据悉，诺辉健康的股份登记处卓佳向曾代客户提交认购申请的券商发信指，按港交所要求，券商需要向港交所确认已采取合适的措施，以拒绝任何重复申请或疑似重复申请；同时，券商要提交认购诺辉健康客户的姓名及身份证号码等资料予港交所，亦要通知诺辉的保荐人已经提交相关资料。港交所回应表示不针对个别公司。主营癌症筛查的诺辉健康招股获106万人热捧，最终只有约逾7万人中签，一手中签率仅2%，比快手的4%更低。","news_type":1,"symbols_score_info":{"06606":0.9}},"isVote":1,"tweetType":1,"viewCount":2350,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":385647285,"gmtCreate":1613549900848,"gmtModify":1613549900848,"author":{"id":"3521540189936763","authorId":"3521540189936763","name":"小王爱大大王","avatar":"https://static.tigerbbs.com/c1fd3513a8e4f9a55a759280c02468d9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3521540189936763","authorIdStr":"3521540189936763"},"themes":[],"htmlText":"老虎应该改改，不中签不要收手续费，太坑了","listText":"老虎应该改改，不中签不要收手续费，太坑了","text":"老虎应该改改，不中签不要收手续费，太坑了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/385647285","repostId":"1196691710","repostType":4,"repost":{"id":"1196691710","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1613549769,"share":"https://ttm.financial/m/news/1196691710?lang=&edition=full","pubTime":"2021-02-17 16:16","market":"hk","language":"zh","title":"老虎暗盘：诺辉健康开涨162%，此前获逾4133倍认购","url":"https://stock-news.laohu8.com/highlight/detail?id=1196691710","media":"老虎资讯综合","summary":"2月17日消息，诺辉健康-B暗盘报70港元，较发行价涨162.57%。公司发行约7659.8万股股份，每股定价26.66港元，每手500股，将于2月18日（周四）港股上市。在此前的公开认购阶段，共有","content":"<p><b>2月17日消息，<a href=\"https://laohu8.com/S/06606\">诺辉健康-B</a>暗盘报70港元，较发行价涨162.57%。公司发行约7659.8万股股份，每股定价26.66港元，每手500股，将于2月18日（周四）港股上市。</b><img src=\"https://static.tigerbbs.com/ac09d2142498bcf317fc057fe1536158\" tg-width=\"750\" tg-height=\"1294\" referrerpolicy=\"no-referrer\"></p><p>在此前的公开认购阶段，共有1,063,663人申购诺辉健康，中签人数76,490人，一手中签率2%，认购倍数达4133.19倍。老虎资讯整理相关数据如下表：<img src=\"https://static.tigerbbs.com/05d546c1be974b505d349f956d8658b3\" tg-width=\"661\" tg-height=\"550\" referrerpolicy=\"no-referrer\"><b>分配结果：</b></p><p>甲组每手500股，一手中签率2%。</p><p>需乙组认购200万股（4000手）方稳中一手500股。<img src=\"https://static.tigerbbs.com/ebc07542a75ef18591d5415a55c16aa6\" tg-width=\"745\" tg-height=\"794\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/7a060274fadd6169c849322b4425b274\" tg-width=\"739\" tg-height=\"509\" referrerpolicy=\"no-referrer\">筹资用途方面，公司所得款项净额约为18.99亿港元将用作以下用途：约40%将分配用于为常卫清(作为医疗服务或独立产品)的商业化及进一步开发提供资金；约5%将分配用于通过提高结直肠癌筛查意识及提升市场渗透率为噗噗管的持续销售及营销提供资金，并在不同人群中进行更多噗噗管的临床评估；约30%将分配用于为正在进行及计划进行的研发提供资金以进一步发展幽幽管、宫证清及其他处于早期阶段的管线产品；约15%将用于通过潜在收购或外部引进癌症筛查领域的候选产品持续扩大及多元化公司的产品组合；及约10%将用作公司的营运资金及其他一般企业用途。</p><p>据悉，诺辉健康于2015年11月成立，是中国结直肠癌筛查市场的先行者，旨在推进技术创新，并加快癌症筛查技术于中国的采用。</p><p>根据弗若斯特沙利文，公司专有的非侵入性多靶点FIT-DNA测试-常卫清为中国首个且唯一一个获国家药监局批准的分子癌症筛查测试产品。公司专注于设计、开发癌症筛查测试及将其商业化，其两大居家结直肠癌筛查测试产品常卫清及噗噗管协同处理不同风险程度的目标人群。</p><p>财务状况方面，于2018~2019财年，公司共录得的总收入分别为1881.6万和5827.5万港元，同比增长209.7%，同期净亏损分别为2.249亿、1.065亿港元；2019年、2020年的截至9月30止的前九个月，总收入分别为3544万、3530.9万港元，同期净亏损分别为6250.8万、5.3亿港元。<img src=\"https://static.tigerbbs.com/db7786daf3aae22f7392f1a5dc492972\" tg-width=\"645\" tg-height=\"753\" referrerpolicy=\"no-referrer\">行业方面，中国是全球结直肠癌发病数最高的国家，2015年的38.8万宗确诊病例增加至2019年的44万宗确诊病例，复合年增长率为3.2%。根据弗若斯特沙利文，结直肠癌的治疗成本为中国医疗体系带来沉重的经济负担，整体人均开支于中国城市地区常见的癌症类型中为最高。</p><p>由于发病数高、死亡数高、肿瘤发展周期长及治疗负担沉重，结直肠癌在无癌症体征或症状的中等风险人群中属于少数建议定期筛查的癌症类型之一。</p><p>据悉，中国的结直肠癌筛查市场由2015年的人民币2,500百万元增加至2019年的人民币3,000百万元，复合年增长率为4.8%，并预计2030年将进一步增加至人民币19,800百万元，复合年增长率为18.7%。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>老虎暗盘：诺辉健康开涨162%，此前获逾4133倍认购</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n老虎暗盘：诺辉健康开涨162%，此前获逾4133倍认购\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-02-17 16:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>2月17日消息，<a href=\"https://laohu8.com/S/06606\">诺辉健康-B</a>暗盘报70港元，较发行价涨162.57%。公司发行约7659.8万股股份，每股定价26.66港元，每手500股，将于2月18日（周四）港股上市。</b><img src=\"https://static.tigerbbs.com/ac09d2142498bcf317fc057fe1536158\" tg-width=\"750\" tg-height=\"1294\" referrerpolicy=\"no-referrer\"></p><p>在此前的公开认购阶段，共有1,063,663人申购诺辉健康，中签人数76,490人，一手中签率2%，认购倍数达4133.19倍。老虎资讯整理相关数据如下表：<img src=\"https://static.tigerbbs.com/05d546c1be974b505d349f956d8658b3\" tg-width=\"661\" tg-height=\"550\" referrerpolicy=\"no-referrer\"><b>分配结果：</b></p><p>甲组每手500股，一手中签率2%。</p><p>需乙组认购200万股（4000手）方稳中一手500股。<img src=\"https://static.tigerbbs.com/ebc07542a75ef18591d5415a55c16aa6\" tg-width=\"745\" tg-height=\"794\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/7a060274fadd6169c849322b4425b274\" tg-width=\"739\" tg-height=\"509\" referrerpolicy=\"no-referrer\">筹资用途方面，公司所得款项净额约为18.99亿港元将用作以下用途：约40%将分配用于为常卫清(作为医疗服务或独立产品)的商业化及进一步开发提供资金；约5%将分配用于通过提高结直肠癌筛查意识及提升市场渗透率为噗噗管的持续销售及营销提供资金，并在不同人群中进行更多噗噗管的临床评估；约30%将分配用于为正在进行及计划进行的研发提供资金以进一步发展幽幽管、宫证清及其他处于早期阶段的管线产品；约15%将用于通过潜在收购或外部引进癌症筛查领域的候选产品持续扩大及多元化公司的产品组合；及约10%将用作公司的营运资金及其他一般企业用途。</p><p>据悉，诺辉健康于2015年11月成立，是中国结直肠癌筛查市场的先行者，旨在推进技术创新，并加快癌症筛查技术于中国的采用。</p><p>根据弗若斯特沙利文，公司专有的非侵入性多靶点FIT-DNA测试-常卫清为中国首个且唯一一个获国家药监局批准的分子癌症筛查测试产品。公司专注于设计、开发癌症筛查测试及将其商业化，其两大居家结直肠癌筛查测试产品常卫清及噗噗管协同处理不同风险程度的目标人群。</p><p>财务状况方面，于2018~2019财年，公司共录得的总收入分别为1881.6万和5827.5万港元，同比增长209.7%，同期净亏损分别为2.249亿、1.065亿港元；2019年、2020年的截至9月30止的前九个月，总收入分别为3544万、3530.9万港元，同期净亏损分别为6250.8万、5.3亿港元。<img src=\"https://static.tigerbbs.com/db7786daf3aae22f7392f1a5dc492972\" tg-width=\"645\" tg-height=\"753\" referrerpolicy=\"no-referrer\">行业方面，中国是全球结直肠癌发病数最高的国家，2015年的38.8万宗确诊病例增加至2019年的44万宗确诊病例，复合年增长率为3.2%。根据弗若斯特沙利文，结直肠癌的治疗成本为中国医疗体系带来沉重的经济负担，整体人均开支于中国城市地区常见的癌症类型中为最高。</p><p>由于发病数高、死亡数高、肿瘤发展周期长及治疗负担沉重，结直肠癌在无癌症体征或症状的中等风险人群中属于少数建议定期筛查的癌症类型之一。</p><p>据悉，中国的结直肠癌筛查市场由2015年的人民币2,500百万元增加至2019年的人民币3,000百万元，复合年增长率为4.8%，并预计2030年将进一步增加至人民币19,800百万元，复合年增长率为18.7%。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/5b3b5e72649367d0aafd9bcbbca9bcd1","relate_stocks":{"06606":"诺辉健康"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196691710","content_text":"2月17日消息，诺辉健康-B暗盘报70港元，较发行价涨162.57%。公司发行约7659.8万股股份，每股定价26.66港元，每手500股，将于2月18日（周四）港股上市。在此前的公开认购阶段，共有1,063,663人申购诺辉健康，中签人数76,490人，一手中签率2%，认购倍数达4133.19倍。老虎资讯整理相关数据如下表：分配结果：甲组每手500股，一手中签率2%。需乙组认购200万股（4000手）方稳中一手500股。筹资用途方面，公司所得款项净额约为18.99亿港元将用作以下用途：约40%将分配用于为常卫清(作为医疗服务或独立产品)的商业化及进一步开发提供资金；约5%将分配用于通过提高结直肠癌筛查意识及提升市场渗透率为噗噗管的持续销售及营销提供资金，并在不同人群中进行更多噗噗管的临床评估；约30%将分配用于为正在进行及计划进行的研发提供资金以进一步发展幽幽管、宫证清及其他处于早期阶段的管线产品；约15%将用于通过潜在收购或外部引进癌症筛查领域的候选产品持续扩大及多元化公司的产品组合；及约10%将用作公司的营运资金及其他一般企业用途。据悉，诺辉健康于2015年11月成立，是中国结直肠癌筛查市场的先行者，旨在推进技术创新，并加快癌症筛查技术于中国的采用。根据弗若斯特沙利文，公司专有的非侵入性多靶点FIT-DNA测试-常卫清为中国首个且唯一一个获国家药监局批准的分子癌症筛查测试产品。公司专注于设计、开发癌症筛查测试及将其商业化，其两大居家结直肠癌筛查测试产品常卫清及噗噗管协同处理不同风险程度的目标人群。财务状况方面，于2018~2019财年，公司共录得的总收入分别为1881.6万和5827.5万港元，同比增长209.7%，同期净亏损分别为2.249亿、1.065亿港元；2019年、2020年的截至9月30止的前九个月，总收入分别为3544万、3530.9万港元，同期净亏损分别为6250.8万、5.3亿港元。行业方面，中国是全球结直肠癌发病数最高的国家，2015年的38.8万宗确诊病例增加至2019年的44万宗确诊病例，复合年增长率为3.2%。根据弗若斯特沙利文，结直肠癌的治疗成本为中国医疗体系带来沉重的经济负担，整体人均开支于中国城市地区常见的癌症类型中为最高。由于发病数高、死亡数高、肿瘤发展周期长及治疗负担沉重，结直肠癌在无癌症体征或症状的中等风险人群中属于少数建议定期筛查的癌症类型之一。据悉，中国的结直肠癌筛查市场由2015年的人民币2,500百万元增加至2019年的人民币3,000百万元，复合年增长率为4.8%，并预计2030年将进一步增加至人民币19,800百万元，复合年增长率为18.7%。","news_type":1,"symbols_score_info":{"06606":0.9}},"isVote":1,"tweetType":1,"viewCount":3771,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}